Business Wire

CA-DIC

28.7.2021 09:57:05 CEST | Business Wire | Press release

Share
DIC, Debut Biotech Team Up to Develop and Bio-Manufacture Natural Pigments for More Sustainable Food Colorants and Cosmetics

DIC Corporation (TOKYO:4631) announced a joint research development agreement with California-based biotech startup Debut Biotechnology , Inc., further enhancing DIC efforts to develop natural pigments for food colorants and cosmetics.

In recent years, increasingly urgent climate concerns have increased global consumer demand for biodegradable, naturally derived colorants—notably in foods and cosmetics—to replace synthetic petroleum-derived colorants. This rapidly increasing consumer demand has motivated major global brands to seek out more sustainable materials for their products.

Unfortunately, the increasing efforts to extract useful pigments from natural materials, including flowers or plants, continue to face significant commercialization challenges, including unacceptably low yields, excessive post-extraction waste generation, and environmental burdens, such as land and water use. Moreover, problems specific to agriculture, such as increasingly unstable weather as well as qualitative and quantitative fluctuations remain as barriers to efficient production.

While more organizations are now researching ways to efficiently culture bacteria, yeast, or algae, etc., using biological reactions within cells to produce needed materials, the by-products generated by these reactions continue to foil attempts to conduct reaction processes under optimum conditions.

Debut’s proprietary next-generation continuous cell-free biomanufacturing technology overcomes these traditional biomanufacturing barriers—retaining enzymes and other useful parts of cells, while discarding limiting parts. By working with vital cell enzymes and such under optimum conditions, Debut Biotech engineers optimize reactions, synthesizing stable targets with high purity to efficiently and continuously manufacture biomaterials and other active ingredients previously overlooked due to low material yields.

Debut, CEO Joshua Britton said, “With our advanced cell-free biomanufacturing platform, we’re able to produce color ingredients that are simply not possible with traditional fermentation-based biomanufacturing. Our colors are naturally-derived with a fraction of the inputs—less waste and energy—and without the use of petrochemicals. With this approach, we’re able to take on a level of complexity that creates whole new possibilities for the color ingredient landscape across industries. We’re thrilled to be working with DIC as they’re established leaders in the color ingredients industry.”

DIC Managing Executive Officer Kiyofumi Takano said, “DIC hopes to combine Debut's advanced knowledge of enzyme reactions and process design with DIC’s scale-up technology, quality control, and product development capabilities to develop and commercialize new sustainable, high value-added bio-based colorants, pigments, and healthy foods for global markets.”

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Europe Reaffirms Commitment to Patient-Centred Care with Extensive Data Showcase at EAS Congress 202626.5.2026 17:00:00 CEST | Press release

Presentations at the 94th European Atherosclerosis Society (EAS) Congress highlight the breadth of evidence for bempedoic acid across a wide range of patient subgroups and background therapies. Real-world data from the MILOS study across multiple European cohorts demonstrate consistent effectiveness and safety profile in routine clinical practice.1,2,3,4 Analysis from the CLEAR Outcomes trial underscores the impact of bempedoic acid on cardiovascular risks, including stroke and venous thromboembolism (VTE).5,6 Daiichi Sankyo Europe’s commitment to "care for every heartbeat" is centred on providing accessible oral treatment options to ensure every patient is given a chance to reach their LDL-C goals. Daiichi Sankyo Europe (DSE) is pleased to announce its extensive scientific presence at the European Atherosclerosis Society (EAS) Congress 2026. The presentation of 15 abstracts, comprising both clinical trial analyses and real-world evidence, underscores the company's sustained investment

OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release

NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi

Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release

Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in

Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release

Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar

ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release

First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye